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Abstract
Genomic instability, a hallmark of almost all human can-
cers, drives both carcinogenesis and resistance to thera-
peutic interventions. Pivotal to the ability of a cell to main-
tain genome integrity are mechanisms that signal and repair
deoxyribonucleic acid (DNA) double-strand breaks
(DSBs), one of the most deleterious lesions induced by ion-
ising radiation and various DNA-damaging chemicals. On
the other hand, many current therapeutic regimens that ef-
fectively kill cancer cells are based on the induction of ex-
cessive DSBs. However, these drugs often lack selectivity
for tumour cells, which results in severe side effects for
the patients, thus compromising their therapeutic potential.
Therefore, the development of novel tumour-specific treat-
ment strategies is required.
Unlike normal cells, however, cancer cells are often char-
acterised by abnormalities in the DNA damage response in-
cluding defects in cell cycle checkpoints and/or DNA re-
pair, rendering them particularly sensitive to the induction
of DSBs. Therefore, new anticancer agents designed to ex-
ploit these vulnerabilities are becoming promising drugs
for enhancing the specificity and efficacy of future cancer
therapies. Here, we summarise the latest preclinical and
clinical developments in cancer therapy based on the cur-
rent knowledge of DSB signalling and repair, with a special
focus on the combination of small molecule inhibitors with
synthetic lethality approaches.
Key words: genomic instability; DNA damage response;
DNA repair; cancer therapy; small molecule inhibitors;
synthetic lethality
Introduction
Cancer is the major cause of death in Switzerland among
people aged 45–84 years [1]. The latest Swiss cancer stat-
istics indicate that prostate cancer in men and breast cancer
in women are the most common types, with 6,000 and
5,500 incidences per year, respectively. Notably, lung can-
cer is still the leading cause of cancer-related death in
the Swiss population, accounting for approximately 3,000
deaths each year [2].
Almost all human cancers are characterised by genomic
instability, which is considered to play a key role in the
conversion of a normal cell into a premalignant cell [3].
Mechanisms contributing to genomic instability include
aberrant repair of deoxyribonucleic acid (DNA) lesions as
well as defective signalling to cell-cycle checkpoints and
induction of apoptosis. Damaging agents, emanating from
endogenous and environmental sources such as oxidative
stress and ultraviolet (UV) radiation, constantly challenge
the integrity of DNA. Remarkably, spontaneous DNA dam-
age, mostly hydrolytic cytosine deamination and oxidative
DNA base damage, occurs at a rate of up to 105 lesions per
cell per day [4, 5].
In order to counteract these insults and preserve genome
stability, cells activate a coordinated signal-transduction
network, which is collectively known as the DNA damage
response (DDR). Generally, this response consists of a
series of events such as detection of the DNA damage by
sensors, accumulation of repair factors by mediators and
repair of the lesion by effectors [6]. Cells are equipped with
a variety of distinct, but partially compensatory, DNA re-
pair mechanisms, each addressing a specific type of lesion
[5]. DNA double-strand breaks (DSBs) are considered to
be the most hazardous lesions, since a single unrepaired
DSB may trigger cell death whereas a misrepaired DSB
potentially results in mutations such as chromosomal re-
arrangements, which can promote carcinogenesis. There-
fore, activation of cell-cycle checkpoints and faithful repair
in response to DSBs are a primary barrier to malignant
transformation.
The fact that DSBs are highly cytotoxic is exploited in
conventional cancer treatment with radiation therapy and
certain chemotherapeutic drugs such as DNA crosslinkers
and topoisomerase inhibitors. Although those agents in-
duce DSBs in all cells, hyperproliferating cancer cells are
much more susceptible to killing than normal cells.
However, most of these well-established treatments cause
a number of adverse effects, mainly by affecting the fast-
dividing cells of the patient, such as haematopoietic stem
cells, hair follicles and cells lining the stomach and intest-
ines. Therefore, novel strategies to treat cancer are eagerly
anticipated and the subject of extensive research.
In this review, we summarise how DSB repair and its ge-
netic interactions have emerged as targets for improved
cancer treatment strategies in the recent past. We also high-
light the current knowledge of small molecule inhibitors
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(SMIs) of DSB signalling and repair factors, which are
promising candidates for clinical use. For a comprehensive
overview of targeting DDR pathways for cancer therapy,
we direct the reader to recently published reviews [7–9].
DNA damage response
The DDR is a multifaceted signalling network, which is eli-
cited upon detection of DNA lesions in order to coordinate
the cell cycle, DNA repair and possibly senescence or ap-
optosis (fig. 1). Three members of the phosphatidylinosit-
ol-3-kinase (PI3K) related kinases (PIKKs) ‒ ATM (ataxia
telangiectasia mutated), ATR (ATM- and Rad3-related) and
DNA-PKcs (DNA-dependent protein kinase catalytic sub-
unit) ‒ become activated upon DNA damage to trigger the
DDR [10]. Through a cascade of phosphorylation events,
ATM and ATR activate multiple proteins, most notably p53
and the downstream checkpoint kinases CHK1 and CHK2,
which in turn phosphorylate WEE1 kinase and CDC25
phosphatases. Consequently, through regulating the activ-
ity of cyclin-dependent kinases (CDKs), the progression
from one cell cycle phase to another is delayed [11].
Depending on which CDK is inhibited; the cell cycle is ar-
rested either at the G1/S or the G2/M transition. The res-
ulting cell-cycle arrest allows time for repair, thereby pre-
venting genome duplication or cell division in the presence
of damaged DNA. Thus, cells with an abrogated DDR gen-
erally display an increased sensitivity towards DNA-dam-
aging agents.
DNA repair pathways
Depending on the type of DNA damage, cells invoke spe-
cific DNA repair pathways in order to restore the genetic
information (see fig. 1). Briefly, minor changes to DNA
such as oxidised or alkylated bases, small base adducts
and single-strand breaks (SSBs) are restored by the base
excision repair (BER) pathway [4]. A key player in this
process is poly-adenosine-diphosphate-ribose (PAR) poly-
merase (PARP). Upon detection of SSBs, PARP covalently
transfers PAR chains to itself and to acceptor proteins in
the vicinity of the lesion, thereby facilitating the repair of
SSBs. More complex, DNA helix-distorting base lesions,
such as those induced by UV light, are repaired by nuc-
leotide excision repair (NER) [5]. Another kind of dam-
age disturbing the helical structure of DNA is represented
by base mismatches. Mismatch repair factors recognise and
process misincorporated nucleotides as well as insertion or
deletion loops that arise during recombination or from er-
rors of DNA polymerases [12]. Covalent links between the
two strands of the double helix represent a type of DNA
damage referred to as interstrand crosslinks (ICLs). ICLs
represent the most deleterious lesions produced by chemo-
therapeutic agents such as mitomycin C (MMC), cisplat-
in and cyclophosphamide. ICL repair is complex and in-
volves the collaboration of several repair pathways, namely
Fanconi anaemia, NER, translesion synthesis and homo-
logous recombination (HR) [13].
DNA double-strand break repair
Thus far, four mechanistically distinct DSB repair mechan-
isms in mammalian cells have been described: nonhomo-
logous end joining (NHEJ), alternative-NHEJ, single-
strand annealing and HR [14]. NHEJ and HR represent
the two major DSB repair pathways, with NHEJ operating
throughout the cell cycle and HR being most active during
S-phase (fig. 2) [15]. NHEJ starts with the binding of the
Ku70/80 heterodimer to both ends of the break, followed
by the recruitment of the catalytic subunit of DNA-depend-
ent protein kinase (DNA-PKcs). Subsequent phosphoryla-
tion events mediated by the DNA-PK holoenzyme lead to
appropriate DNA end processing by the Artemis nuclease.
DSB repair by NHEJ is completed by rejoining of the ends
Figure 1
The DNA damage response.
Exogenous and endogenous DNA damaging agents generate various types of lesions
including DNA single- and double-strand breaks (SSBs and DSBs). The multifunctional
MRN complex detects DSBs, while FANCM is required for the DNA interstrand crosslink
(ICL)-induced checkpoint response. PARP predominantly acts as a SSB sensor protein.
RPA binds to regions of single-stranded DNA (ssDNA) that are exposed at stalled
replication forks or after DSB resection. MRN and RPA mediate the recruitment of ATM
and ATR-ATRIP, respectively, and the subsequent activation of the respective pathways,
coordinating cell-cycle checkpoints, DNA repair and apoptotic responses to DNA damage.
The Ku70/Ku80 heterodimer (KU) competes with MRN for binding to DSBs. KU recruits
DNA-PKcs to form the catalytically active DNA-PK holoenzyme which is a major
component of the canonical NHEJ machinery during DSB repair. MRN on the other hand
initiates HR (see also fig. 2). Once activated, the DNA damage signalling cascade
extends through multiple phosphorylation events primarily via the cell-cycle checkpoint
kinases CHK1 and CHK2. Their signals converge on downstream effectors such as the
tumour suppressor protein p53 or the CDC25 protein phosphatase and WEE1 tyrosine
kinase. As a result, CDK activity is inhibited, delaying cell cycle progression from G1 to S
(the G1/S checkpoint) or from G2 to M phase (the G2/M checkpoint). The DNA damage
response (DDR) thus orchestrates a variety of cellular outcomes: the transcriptional programme of the damaged cell is altered and the cell
cycle is transiently arrested, thereby facilitating repair of the DNA lesions. In situations where DNA damage is too severe and cannot be
repaired, the DDR triggers apoptosis or senescence.
ADP = adenosine diphosphate; ATM = ataxia telangiectasia mutated protein; ATR = ATM- and Rad3-related; ATRIP = ATR-interacting protein;
CDK = cyclin-dependeant kinase; DNA = deoxyribonucleic acid; DNA-PK = DNA-dependeant protein kinase; DNA-PKcs = DNA-PK catalytic
subunit; FANCM = Fanconi anaemia complementation group M; HR = homologous recombination; ICL = interstrand crosslink; MRN =
MRE11-RAD50-NBS1 complex; NEHJ = nonhomologous end joining; PARP = poly(ADP-ribose) polymerase; RPA = replication protein A
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catalysed by a complex consisting of X-ray repair cross-
complementing protein 4 (XRCC4), XRCC4-like factor
(XLF) and DNA ligase IV. HR takes over if NHEJ is
unsuccessful in ligating the broken DNA ends or when
the DSB is first recognised by the MRE11-RAD50-NBS1
(MRN) complex rather than by Ku70/80 [16]. Together
with CtBP-interacting protein (CtIP; CtBP = C-terminal
binding protein), MRN resects DSBs to generate short 3'-
single-stranded-DNA (ssDNA) tails that get immediately
coated with replication protein A (RPA) [17]. The
BRCA2-PALB2 complex promotes RAD51 nucleation
onto ssDNA, thereby replacing RPA. The RAD51 nucleo-
protein filament then invades the homologous, intact DNA
template forming a displacement loop. The second end of
the broken chromosome is captured and anneals to the
complementary strand of the donor DNA molecule, result-
ing in the formation of two Holliday junctions (HJs). After
DNA synthesis and ligation of both strands, the double HJ
is either dissolved or is dismantled by the catalytic action
of resolvases in order to complete repair [18]. Thus, re-
pair by HR is error-free since it copies the missing genetic
information from the undamaged sister chromatid, where-
as NHEJ is error-prone since DNA ends without sequence
homology are religated with the risk of causing mutations
[19]. Given that a single unrepaired DSB has the potential
to kill a cell, inhibition of repair by compounds that target
factors involved in NHEJ or HR will increase the sensitiv-
ity of cancer cells to DSB-inducing anticancer agents.
Harnessing DNA damage signalling
and repair for cancer therapy
The fact that cells with a compromised DDR are hypersens-
itive to DNA damage-inducing agents is currently under
vigorous investigation for use in targeted cancer therapy.
More precisely, during their pathogenesis, many cancer
cells acquire defects in a certain DNA repair pathway and
become dependent on a compensatory mechanism in or-
der to survive. Hence, pharmacological inhibition of the
“backup” pathway in combination with DNA damage will
selectively kill cancer cells but spare their normal counter-
parts. Furthermore, highly proliferative cancer cells are in-
herently hypersensitive to DNA damage because S-phase,
in which DNA replication takes place, is the most vulner-
able period of the cell cycle.
Targeting DSB signalling pathways
As previously mentioned, cell-cycle checkpoint activation
in response to DSBs gives a cell time for DNA repair be-
fore entry into S-phase or mitosis. Consequently, cell-cycle
checkpoints reduce the efficacy of DNA-damaging agents
used in cancer therapy. Therefore, selective abrogation of
checkpoint signalling sensitises cancer cells to chemo- and
radio-therapy, potentiating cancer treatment [20]. Import-
antly, more than 50% of human tumours are defective in
p53 tumour suppressor function and cell-cycle checkpoint
inhibitors have been demonstrated particularly to sensitise
p53-deficient cancer cells to various anticancer agents in
clinical use [21].
In the late 1960s, long before the discovery of cell-cycle
checkpoints, the first attempts to sensitise cancer cells to
standard cytotoxic therapy were made using ordinary com-
pounds such as caffeine [22]. Later it was found that caf-
feine directly binds to and inhibits ATM and ATR in vitro
and thus interferes with initiation of the DDR [23, 24].
However, since caffeine is a relatively nonselective agent,
efforts have been made to develop more potent and se-
lective inhibitors of the PIKK family members ATM, ATR
and DNA-PKcs (table 1). In 2004, KuDOS Pharmaceut-
icals (now AstraZeneca) reported the identification of
KU-55933, a specific SMI of ATM [25]. On the molecular
level, KU-55933, like most kinase inhibitors, competes
with the ATP-binding site of the enzyme, thereby inhibiting
the catalytic activity of ATM [26]. Based on the promising
preclinical results, KU-60019, a KU-55933 analogue with
Figure 2
DNA double-strand break (DSB) repair.
DSBs are predominantly repaired by two distinct pathways: NHEJ
or HR. NHEJ operates throughout the cell cycle, but mainly during
the G1 and G2 phases, whereas HR peaks in S phase. Rapid
association of the Ku70/80 heterodimer to DSBs promotes NHEJ
by recruiting DNA-PKcs. DNA ends are processed by the
nucleolytic activity of Artemis, followed by religation catalysed by a
complex of XLF, Ligase IV (Lig4) and XRCC4. Alternatively, MRN,
which is initially recruited to DSBs in competition with Ku70/80,
initiates DSB resection together with CtIP thereby promoting HR.
53BP1 antagonises BRCA1 in DSB resection. Extensive DSB
resection by other nucleases and formation of RPA-coated ssDNA
stimulates the activation of ATR. Displacement of RPA by RAD51 is
mediated by BRCA2 and PALB2, resulting in the formation of
RAD51 nucleoprotein filaments. Subsequent strand invasion into
the homologous DNA template and capturing of the second DNA
end leads to the formation of a double Holliday junction, which is
processed by resolvases. Finally, the DNA is sealed by ligases to
accomplish error-free repair of the DSB.
53BP = p53 binding protein; ATM = ataxia telangiectasia mutated
protein; CtBP = C-terminal binding protein; CtIP = CtBP-interacting
protein; DNA = deoxyribonucleic acid; DNA-PK = DNA-dependent
protein kinase; DNA-PKcs = DNA-PK catalytic subunit; HR =
homologous recombination; MRN = MRE11-RAD50-NBS1
complex; NHEJ = nonhomologous end joining; PALB1/2 = partner
and localiser of BRCA1/2; RPA = replication protein A; ssDNA =
single-stranded DNA; XLF = XRCC4-like factor; XRCC4 = X-ray
repair cross-complementing protein 4
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improved pharmacokinetics and bioavailability, was syn-
thesised and shown to radiosensitise glioma cells approx-
imately 10 times more efficiently than KU-55933 [27].
Compounds selectively targeting ATR have long been
awaited, particularly when inhibitors of CHK1, a direct
downstream target of ATR, had proven to be clinically
effective [28]. Finally, in 2011, three ATR inhibitors,
NU-6027, VE-821 and ETP-46464 were described.
NU-6027 is a pyrimidine analogue originally discovered
as an adenosine triphosphate (ATP) competitive inhibitor
of CDKs, but recently reported also to inhibit ATR at low
micromolar concentrations and to confer cisplatin cytotox-
icity independently of CDK inhibition [29, 30]. The ATR
inhibitor VE-821 (Vertex Pharmaceuticals) was identified
using a high-throughput screen against full-length recom-
binant ATR [31]. Preclinical testing of VE-821 using pan-
creatic cancer cells demonstrated its chemo- and radio-
sensitisation properties [32]. ETP-46464 was discovered
by screening compounds with a previously reported activ-
ity against the related PI3Ks using a cell-based system as-
saying for ATR activity [33]. In the same study, NVP-
BEZ235, a recognised dual PI3K/mTOR inhibitor (mTOR
= mammalian target of rapamycin), was also reported to
block efficiently ATM, ATR and DNA-PK activity. Fur-
thermore, NVP-BEZ235 was found to act as a radio- and
chemo-sensitiser in various cancer cell lines and is cur-
rently being tested as a single agent in various Phase I/II
clinical trials [34, 35]. Importantly, most, if not all, of the
aforementioned compounds are likely to inhibit additional
protein kinases, especially when used at concentrations in
the high micromolar range, thus potentially exhibiting “off-
target” effects.
Downstream of ATM and ATR act the two transducer
kinases CHK1 and CHK2, against which several inhibitors
have emerged during recent years. One of the first SMIs,
UCN-01, a derivative of staurosporine, was originally isol-
ated from a Streptomyces strain as a protein kinase antag-
onist with cytotoxic effects [36]. UCN-01 was later shown
to be a potent inhibitor of CHK1 and to block its kinase
activity by interacting with the ATP-binding pocket [37,
38]. Six Phase II clinical trials of UCN-01, either as a
single agent or in combination with other drugs, in patients
with different types of advanced cancer have already been
completed. Recently, three novel CHK1 inhibitors,
GDC-0425 (Genentech Inc.), SCH900776 (now renamed
MK-8776, Merck) and LY-2606368 (Eli Lilly), have
entered Phase I clinical trials either as single agents or in
combination with gemcitabine, a nucleoside analogue [39].
Another promising drug that interferes with checkpoint ac-
tivation is the WEE1 tyrosine kinase inhibitor MK-1775
(Merck), which was discovered by screening a chemical
library [40]. MK-1775 is already under investigation in a
Phase II trial combined with carboplatin in order to assess
the benefit for patients with p53-mutated epithelial ovarian
cancer. Last but not least, efforts to target CDC25 phos-
phatases, which also represent key molecules in checkpoint
regulation, led to the discovery of several CDC25 inhib-
itors, amongst which the most potent are quinonoid-based
derivatives such as the bis-quinone compound IRC-08386
[41, 42].
In summary, several SMIs that interfere with checkpoint
activation show great promise of advancing in clinical
studies and eventually being used as chemo- or radio-sens-
itisers as well as monotherapeutic agents in cancer treat-
ment. Nevertheless, since many of the SMIs have only very
recently been discovered, their safety, tolerability and ef-
ficacy when used alone or in combination has to be further
investigated.
Targeting DSB repair
Impairing the repair of DSBs using drugs that either inhibit
the enzymatic activity or interfere with protein-protein in-
teractions of repair factors provides another approach to
sensitising cancer cells for chemo- and radio-therapy. A
key player in DSB repair by NHEJ is DNA-PK (see fig. 1),
which, like ATM and ATR, belongs to the PIKK family of
protein kinases. In 2003, two DNA-PKcs-specific inhibit-
ors, NU-7026 and NU-7441, were reported, both of which
are practically inactive against ATM and ATR [43, 44]. Un-
fortunately, neither of them has progressed into clinical de-
velopment. However, Celgene Corporation is currently re-
cruiting patients with advanced tumours unresponsive to
standard therapies in order to test the pharmacokinetics and
preliminary efficacy of the dual DNA-PK/mTOR inhibit-
or, CC-115, in a Phase I trial. Moreover, a very recent
preclinical study reported that KU-60648 (AstraZeneca),
a dual inhibitor of DNA-PK and PI3K, acts as a chemo-
sensitiser in cell-based assays and in mice xenografts [45].
More recent attempts to find novel DSB repair inhibitors
led to the identification of mirin, the first inhibitor of the
MRN complex that acts by blocking the nuclease activity
of MRE11 [46]. Interestingly, mirin was shown to kill
BRCA2-deficient cells, an effect that was even more pro-
nounced when combined with a PARP inhibitor [47].
However, since mirin has to be applied at high micromolar
concentrations to inhibit MRN, such treatment is prone to
increase the risks of undesired “off-target” effects and the
generation of more selective derivatives is eagerly anticip-
ated.
During the course of DSB repair by HR, ssDNA is gen-
erated and immediately coated by RPA, which later on is
replaced by the RAD51 recombinase (see fig. 2). Inhibit-
ing the DNA-binding activity of RPA by the SMI MCI13E
yielded encouraging preclinical results in combination with
cisplatin [48]. Moreover, several means to prevent RAD51
action have been reported, including SMIs (B02, RI-1) as
well as inhibitory peptides that interfere with the binding
of BRCA2 to RAD51 [49–52]. Although peptides blocking
protein-protein interactions represent an interesting
concept for inhibiting DSB repair, their potential applica-
tion in the clinics has yet to be established.
In summary, safety, tolerability, pharmacokinetics and ef-
ficacy of most of the aforementioned SMIs have still to be
carefully validated before they may enter clinical trials to
examine their benefit for cancer therapy.
Synthetic lethality approaches to
target DSB repair-deficient cancers
Mutations in DSB repair genes render cancer cells depend-
ent on alternative DNA repair pathways. Thus, comprom-
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ised abilities to repair DSBs confer a weakness that can be
therapeutically exploited on the basis of the concept of syn-
thetic lethality, whereby inhibition of the “back-up” path-
way induces greater toxicity in DSB repair-deficient cancer
cells as compared with normal cells (fig. 3).
PARP inhibitors
The first “proof-of-principle” study verifying synthetic
lethality as a suitable approach for targeted cancer therapy
was published in 2005, after it had been demonstrated that
HR-defective BRCA1- or BRCA2-deficient cell lines dis-
play dramatically increased sensitivity to inhibition of the
SSB repair enzyme PARP [53, 54]. Subsequently, clinical
development of potent small molecule PARP inhibitors
(PARPis) rapidly advanced, and the first Phase II results
in 2009 showed that monotherapy with the PARPi olaparib
(AZD-2281; AstraZeneca) achieved encouraging response
rates of 41% and 33% in patients with BRCA1- or
BRCA2-mutated advanced breast and ovarian cancers, re-
spectively [55, 56]. Furthermore, preclinical studies sug-
gested the potential use of PARPi also in sporadic cancers
that share phenotypical features with cancers arising from
hereditary BRCA mutations, a phenomenon that is referred
to as “BRCAness” [57]. Reasons for “BRCAness” can be
the inactivation of BRCA1 or BRCA2 function caused by
aberrant epigenetic or posttranslational modifications, or a
wider range of mutations in other genes resulting in de-
fective DSB signalling and HR. For example, it was repor-
ted that depletion of factors such as ATR, ATM, CHK1,
CHK2, NBS1, CtIP and RAD51 in cultured cells syner-
gistically increases PARPi cytotoxicity to an extent similar
to mutations in BRCA1/2. This indicates that BRCA-defi-
cient cells are, at least in part, sensitive to PARP inhibi-
tion because of a defect in HR [58, 59]. The current un-
derstanding suggests that inhibition of PARP leads to the
accumulation of SSBs which are converted into DSBs upon
encountering DNA replication forks during S-phase when
HR is most active [60]. Consequently, in the absence of
functional HR, such as in cancer cells lacking BRCA1 or
BRCA2, PARP inhibition results in the accumulation of
DSBs and, ultimately, in apoptosis or mitotic catastrophe.
Importantly, normal cells survive the treatment owing to
functional HR, providing the kind of selectivity that is con-
sidered the ultimate goal of cancer therapy. Nowadays,
most PARPi in preclinical and clinical trials belong to the
third generation of SMIs designed to compete with the
substrate nicotine adenine dinucleotide (NAD+) resulting
in reversible inhibition of PARP. Recent reports indicate
that in addition to catalytic inhibition, some PARPi induce
cytotoxic PARP–DNA complexes, trapping PARP proteins
on damaged DNA. Currently, PARPi are divided into two
classes: catalytic inhibitors and dual inhibitors that not only
block the enzymatic activity but also act as so-called PARP
“poisons” [61, 62].
Today, 7 years after PARPi were first established for cancer
therapy and despite some quite promising clinical studies,
none of them has gained official approval for the treatment
of cancer patients. In 2011, encouraging results from a
Table 1: Small molecule inhibitors of DNA damage response factors in preclinical or clinical development for cancer therapy.
Target Inhibitor Mono- or combination therapy / clinical study stage Clinical trial identifier/
reference
KU-55933 IR, etoposide, doxorubicin, camptothecin, in preclinical testing [25, 95]ATM
KU-60019 IR in preclinical testing using glioma cells [27]
NU-6027 Hydroxyurea, cisplatin, temozolomide, rucaparib in preclinical testing [29]
VE-821 Cisplatin in breast and ovarian cell lines
IR, gemcitabine in pancreatic cancer cells in preclinical testing
[31, 96]
[32]
ATR
ETP-46464 Single agent in p53-deficient cancer cells in preclinical testing [33]
NU-7441 IR, etoposide in preclinical testing of cancer cell lines and tumour xenografts [44, 97]DNA-PKcs
NU-7026 IR and combined with AG14361 (PARPi) in preclinical testing
Anthracyclines, mitoxantrone, etoposide in preclinical testing using leukaemia cells
[43]
[98]
DNA-PKcs/PI3K KU-60648 Etoposide, doxorubicin in preclinical testing [45]
DNA-PKcs/mTOR CC-115 Single agent in Phase I safety and tolerability study (recruiting) NCT01353625
PI3K/mTOR/PIKK NVP-BEZ235 Single agent in several clinical trials
IR, cisplatin in preclinical testing
www.clinicaltrials.gov
[34, 35]
UCN-01 Single agent in Phase II for relapsed T-cell lymphoma (completed)
Single agent in Phase II for metastatic melanoma (completed)
Five-fluorouracil in Phase II for metastatic pancreatic cancer (completed)
Topotecan in Phase II for various forms of ovarian cancer (completed)
Topotecan in Phase II for small cell lung cancer (completed)
Olaparib in pre-clinical testing for multiple mammary tumour types
NCT00082017
NCT00072189
NCT00045747
NCT00072267
NCT00098956
[99]
GDC-0425 Single agent or with gemcitabine in Phase I dose-escalation study (recruiting) NCT01359696
MK-8776 Single agent or with gemcitabine in Phase I dose-escalation study (completed) NCT00779584
CHK1/(CHK2)
LY-2606368 Single agent in Phase I study in patients with advanced cancer (recruiting) NCT01115790
WEE1 MK-1775 Carboplatin in Phase II for epithelial ovarian cancer NCT01164995
CDC25 IRC-083864 Single agent in preclinical testing using pancreatic and prostate cancer cells [42]
MRE11 mirin Single agent or with olaparib (PARPi) in preclinical testing using BRCA2-deficient cells [47]
RPA MCl13E Single agent or with cisplatin in preclinical testing [48]
B02 IR, mitomycin C, cisplatin in preclinical testing [100]RAD51
RI-1 Mitomyin C in preclinical testing [50]
ADP = adenosine diphosphate; ATM = ataxia telangiectasia mutated protein; ATR = ATM- and Rad3-related; CHK = checkpoint kinase; DNA = deoxyribonucleic acid;
DNA-PK = DNA-dependent protein kinase; DNA-PKcs = DNA-PK catalytic subunit; IR = ionising radiation; mTOR = mammalian target of rapamycin; PAR = poly(ADP-
ribose); PARP = PAR polymerase; PARPi = PARP inhibitor; PI3K = phosphatidylinositol-3-kinase; PIKK = PI3K-related kinase; RPA = replication protein A
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Phase II trial with iniparib (BSI-201, Sanofi-Aventis) in
patients with triple negative breast cancer, which shares
many features with BRCA-associated breast cancer, failed
to translate into overall patient survival in a Phase III trial
[63]. Later that year, AstraZeneca announced that olaparib
would not progress into Phase III for hereditary BRCA
mutation-associated breast cancer. This decision was pos-
sibly driven by economic concerns rather than by clinical
issues [64]. Notwithstanding all setbacks, clinical develop-
ment and research on the mechanism of action of PARPi is
still ongoing (table 2). Despite controversies about its ef-
fectiveness as a PARPi, Sanofi's iniparib is under clinical
investigation as a single agent and in combination with
chemotherapeutic regimens in patients with recurrent solid
tumours (NCT01455532), nonsmall-cell lung cancer
(NCT01082549) and ovarian cancer (NCT01033292) [65,
66]. Likewise, AstraZeneca is continuing Phase II trials
with olaparib to treat serous ovarian cancer, since it shares
many features with BRCA1/2-mutated cancers. Indeed,
activity of olaparib as a monotherapy was evident in wo-
men with pretreated high-grade serous ovarian cancer
without germline BRCA1/2 mutations [67]. This finding
clearly demonstrates positive responses of a subpopulation
of sporadic cancers to PARPi therapy and also underlines
the importance of classifying patients according to bio-
markers in order to predict the efficacy of PARPi. Such
potential biomarkers also include deficiency of the phos-
phatase and tensin homologue (PTEN) tumour suppressor.
Interestingly, due to its role in the regulation of RAD51
Figure 3
Synthetic lethality.
Synthetic lethality is defined as a combination of mutations or
perturbations in two or more genes that leads to cell death,
whereas inactivation of any one of the genes alone does not.
Perturbation of genes can occur through genetic mutation or
silencing, depletion by RNAi or inhibition by SMIs and is depicted
by a red cross. If genes that are essential for a certain DNA repair
pathway (e.g. gene A) are inactivated in normal cells, alternative
pathways with functional genes (e.g. gene B) are utilised to
respond to DNA damage. Conversely, cancer cells mutated or
silenced for a component of a DDR pathway are compromised in
their ability to process DSBs. These cells then rely on alternative
DNA repair pathways to repair the breaks. Therefore, inhibition of
the alternative pathway will cause cell death due to persisting
DSBs. Please refer to main text for details about the example given
for synthetic lethality between BRCA1/2 mutation and PARP
inhibition.
ADP = adenosine diphosphate; BER = base excision repair; DDR =
DNA damage response; DNA = deoxyribonucleic acid; DSB =
double-strand break; HR = homologous recombination; PARP =
poly(ADP-ribose) polymerase; RNA = ribonucleic acid; RNAi = RNA
interference; SMI = small molecule inhibitor
transcription, loss of PTEN is associated with defective
HR [68, 69]. In general, detection of compromised HR
provides a rationale to stratify patients for PARPi treat-
ment. Several ways of identifying HR defects are under in-
vestigation, including gene expression profiling and gene
copy number analysis of DNA repair factors [70, 71]. Fur-
ther approaches assess the DSB repair capacity of tumours
by measuring expression of the MRN complex, monitoring
RAD51 foci formation and poly(ADP-ribosyl)ation as sur-
rogate markers for DSB repair proficiency [72]. As for
most cancer therapies, a major challenge of using PARPis
is the acquired resistance of initially PARPi-sensitive can-
cer cells due, for example, to the loss of 53BP1 (a p53
binding protein) or to overexpression of multidrug-resist-
ance efflux transporters [72, 73]. In addition, secondary
BRCA2 mutations have been identified, which restore the
full-length protein thereby re-establishing BRCA2 func-
tions and conferring PARPi resistance [74].
Thus, despite considerable efforts to develop PARPi for
clinical use, conventional DNA-damaging chemo- and
radio-therapy largely remains the mainstay of cancer treat-
ment. However, several onging preclinical and clinical
studies employ PARPi both as monotherapy and as chemo-
or radio-sensitisers, because an improvement of current
anti-cancer regimes is long-awaited.
Synthetic lethal strategies emerging from preclinical
research
As intensive basic research is leading towards a better un-
derstanding of cellular functions and their underlying ge-
netic networks, more and more genetic interactions become
apparent as potential targets for synthetic lethality in cancer
therapy. Beyond BRCA1 and BRCA2, their joint interac-
tion partner PALB2 is emerging as a breast cancer suscept-
ibility gene, thus providing another opportunity for PARPi-
based therapies [75].
PARP inhibition is not the only approach that takes advant-
age of synthetic lethal interactions between two DNA re-
pair pathways, as inhibition of apurinic/apyrimidinic (AP)
endonuclease 1, an essential component of BER, was re-
cently shown to eliminate cancer cells with HR defects
[76]. Moreover, synthetic lethality with components of the
cell-cycle checkpoint machinery could be exploited in can-
cers harbouring activated oncogenes, since oncogene-in-
duced replication stress activates the ATR-CHK1 sig-
nalling pathway. For example, exacerbated toxicity was
reported upon inhibition of CHK1 in lymphoma cells with
upregulated c-Myc expression [77]. This finding under-
scores the concept that cancers with elevated levels of rep-
lication stress rely on intact checkpoint signalling for cell
survival. Replicative stress induces pan-nuclear distribu-
tion of phosphorylated histone variant H2AX (γ-H2AX),
which is a useful biomarker for classification of tumour
biopsies in order to stratify patients [78].
Finally, disruption of the FA repair pathway was shown
to be synthetically lethal with abrogated checkpoint sig-
nalling. More precisely, inactivation of ATM or CHK1 res-
ulted in reduced viability of FA-deficient cells, illustrating
the concept that checkpoint signalling and FA are mutu-
ally compensatory pathways in the maintenance of gen-
ome integrity [79, 80]. These observations highlight the
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usefulness of SMIs, as currently tested for CHK1, to treat
tumours bearing a specific genetic background. Although
many of the strategies that are based on the concept of syn-
thetic lethality have so far only been investigated in pre-
clinical settings, some hold great promise of entering clin-
ical trials soon.
Haploinsufficiency of DDR factors
There is increasing evidence that haploinsufficiency of
DDR components promotes genome instability and drives
tumourigenesis. Dosage insufficiencies of DNA repair
genes might, however, only be unmasked once a cell is
challenged with an increased load of DNA damage such
as oncogene-induced replicative stress [81, 82]. Synthetic
lethal approaches might therefore be applicable not only
in cancer cells with deficiencies, but also in those bearing
haploinsufficiencies for DDR factors. Evidence from gene
targeting studies in mice revealed that, for example, the
loss of one allele of ATR or CtIP is sufficient to cause in-
creased chromosomal aberrations, genomic instability and
tumour susceptibility [83, 84]. This indicates that hetero-
zygous carriers of DDR defects are more prone to develop
tumours once the threshold of endogenous DNA damage
is increased as, for example, in precancerous lesions [85].
However, scientists are just beginning to unravel how hap-
loinsufficiency of DDR genes contributes to carcinogenesis
and how these may be exploited for novel synthetic lethal
approaches in cancer therapy.
Table 2: PARP inhibitors in preclinical or clinical development for cancer therapy*.
Inhibitor Mono- or combination
therapy
Preclinical and clinical study stage Clinical trial identifier/
reference
Single agent Phase II trials showing with promising response rates in patients with BRCA1/ or
BRCA2 mutated advanced breast and ovarian cancers
NCT01078662,
NCT00494234
[55, 56]
Single agent Phase II trial demonstrating efficacy for advanced high-grade serous ovarian cancer
without germline BRCA1/2 mutations, but not with TNBC
NCT00679783
[67]
Cediranib Phase I/II study for treatment of recurrent serous ovarian cancer and TNBC NCT01116648
Single agent and
combinations with other
drugs
Several ongoing Phase I/II trials for various cancers, dose-limiting adverse effects for
combination of olaparib and topotecan
NCT00516438,
NCT00819221,
NCT01296763,
NCT00912743, [101]
Olaparib
(AZD-2281, KU-59436)
AstraZeneca
Cisplatin, radiation Phase I trial to test olaparib as a radio- and/or chemo-sensitiser in combination with
high-dose radiotherapy with or without a daily cisplatin dose in locally advanced
NSCLC
NCT01562210
Single agent and
combinations with other
drugs
Ongoing Phase I/II trials in solid tumours such as sarcomas as well as breast, uterine
and ovarian cancers
NCT01455532,
NCT01033292,
NCT00687687
Gemcitabine/
carboplatin
Promising results from a Phase II trial failed to translate into survival benefit for TNBC
patients with unselected BRCA1/2 status in Phase III
NCT00938652,
NCT01130259,
[63]
Radiotherapy Ongoing Phase I trial of iniparib as radiosensitiser in nonoperable brain metastases NCT01551680
Temozolomide and
radiotherapy
Ongoing Phase I/II trials for newly diagnosed malignant glioblastoma NCT00687765
Iniparib**
(BSI-201)
Sanofi-Aventis
Gemcitabine/
carboplatin
Ongoing Phase III trial in advanced squamous NSCLC NCT01082549
Temozolomide,
carboplatin/paclitaxel
International randomised Phase II trial of veliparib combined with chemotherapy in
BRCA1/2-mutated, metastatic breast cancer
NCT01506609
Single agent Phase I trial for refractory BRCA 1/2-mutated solid cancers; platinum-refractory
ovarian, fallopian tube, or primary peritoneal cancer or basal-like breast cancer
Additional evaluation of BRCA1/2 expression and changes in PAR and γ-H2AX in
peripheral blood mononuclear cells as diagnostic biomarkers
NCT00892736
Veliparib
(ABT-888)
Abbott Laboratories
Single agent and
combinations with
chemo- and radio-
therapy
Phase I and II trials to identify efficient combinatorial regimens in various solid and
lymphoid tumours, promising results in combination with topotecan and
cyclophosphamide
NCT01154426,
NCT01282333,
NCT01386385 and more,
[102-104]
Single agent Phase I/II trials for BRCA1/2-mutated breast or ovarian cancer NCT01482715
Temozolomide Initial Phase I trial as enhancer for chemotherapy in unselected solid tumours; severe
myelosuppression of the combination in Phase II study for previously untreated
metastatic melanoma
[105]
Rucaparib
(AG-014699,
PF-01367338, CO-338)
Cancer Research UK
Clovis Oncology
Pfizer
Single agent and with
carboplatin
Phase I/II testing in advanced solid tumors with and without BRCA mutations
Several biomarkers for therapeutic response are being evaluated concurrently.
NCT01009190,
NCT00664781
Single agent Phase I trial in advanced solid tumours showing that MK-4827 is well tolerated, blocks
PARP and has promising antitumour activity in both BRCA-deficient and sporadic
cancer
[106]Niraparib
(MK-4827)
Merck
Tesaro Inc. Single agent and with
temozolomide
Phase I dose-escalation study for solid tumours and haematological malignancies NCT00749502,
NCT01294735
* For a complete overview of PARPi currently used in clinical trials, we direct the reader to [61, 107].
** Since the primary mechanism of action for iniparib is likely not via inhibition of PARP activity, it is no longer considered to be a bona fide PARPi [65].
ADP = adenosine diphosphate; γ-H2AX = phosphorylated histone variant H2AX; NSCLC = nonsmall cell lung cancer; PARP = poly(ADP-ribose) polymerase; PARPi =
PARP inhibitor; TNBC = triple negative breast cancer
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Conclusions and future perspectives
To date, DSB-inducing agents have been the core com-
ponents of conventional cancer therapy, confirming the ra-
tionale of inflicting excessive DNA damage in order to
kill cancer cells. However, most chemotherapeutic regi-
mens cause severe side effects that limit their therapeutic
potential. As summarised in this review, SMIs and synthet-
ic lethal approaches targeting the individual genetic pro-
file of the tumours are under clinical development, with
the aim to improve the patients' benefit by increasing the
efficacy while lowering the toxicity of cancer treatments.
A prerequisite for personalised therapy is the molecular
characterisation of tumours with reliable biomarkers to as-
sign patients the appropriate treatment. In order to stratify
cancer patients according to their DNA repair status, tu-
mour biopsies can be analysed with immunohistochem-
istry, fluorescence in-situ hybridisation (FISH), gene se-
quencing, expression profiling and other methods [86].
Relevant biomarker assays should ideally predict the func-
tionality of DNA repair pathways, rather than just provid-
ing information about mutations or expression levels of
proteins involved in the DDR. Certainly, such a detailed
molecular profiling of cancer versus normal tissue from a
given patient is critical to maximise the potential of person-
alised cancer drugs in terms of both therapeutic success and
cost-effectiveness.
Recent in-vitro and in-vivo research has deepened our
knowledge about synthetic genetic interactions and put for-
ward alternative ways to treat cancer. Furthermore, by util-
ising ribonucleic acid (RNA) interference technologies,
screens for synthetic lethal interactions of cancer-specific
defects in DNA repair pathways have augmented the dis-
covery of targets for cancer therapy. For example, studies
using MMR-deficient cells lacking human muts homo-
logue 2 (MSH2) revealed synthetic sickness with POLB,
a DNA polymerase acting in BER [87]. Since MSH2 is
mutated in 40% of patients with hereditary nonpolyposis
colorectal cancer, targeted inhibition of POLB potentially
opens new therapeutic applications. Moreover, gaining fur-
ther insights into the structure and mechanism of action of
DNA repair factors such as CtIP will aid the design of new
and more efficient SMIs of the DDR. Recently discovered
inhibitors of RPA and RAD51 are promising candidates,
which are in preclinical testing in order to be approved for
the use in clinical trials soon [48, 50].
Interestingly, the latest scientific progress in the field of mi-
croRNAs (miRNAs) has demonstrated an intensive inter-
play of these small regulatory RNAs with the DDR, includ-
ing DSB repair. Recent studies revealed that DNA dam-
age globally induces miRNA biogenesis and, vice versa,
that numerous miRNAs modulate the expression of DDR
factors [88–90]. Notably, BRCA1 expression was shown to
be downregulated by miR-182, conferring hypersensitivity
to PARPi [91]. Conversely, BRCA1 was demonstrated to
suppress expression of miR-155, an oncogenic miRNA that
is overexpressed in many cancers [92, 93]. These observa-
tions highlight the therapeutic potential of miRNA mimics
or inhibitors in future approaches for cancer therapy [94].
In summary, as the concept of personalised medicine
emerges, tumour-specific defects of DSB repair pathways
represent a promising therapeutic target to be exploited for
the selective elimination of cancer cells. Thus, there is an
air of optimism for targeted cancer therapy through exploit-
ing the DDR of tumour cells in the clinics.
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Figures (large format)
Figure 1
The DNA damage response.
Exogenous and endogenous DNA damaging agents generate various types of lesions including DNA single- and double-strand breaks (SSBs
and DSBs). The multifunctional MRN complex detects DSBs, while FANCM is required for the DNA interstrand crosslink (ICL)-induced
checkpoint response. PARP predominantly acts as a SSB sensor protein. RPA binds to regions of single-stranded DNA (ssDNA) that are
exposed at stalled replication forks or after DSB resection. MRN and RPA mediate the recruitment of ATM and ATR-ATRIP, respectively, and the
subsequent activation of the respective pathways, coordinating cell-cycle checkpoints, DNA repair and apoptotic responses to DNA damage.
The Ku70/Ku80 heterodimer (KU) competes with MRN for binding to DSBs. KU recruits DNA-PKcs to form the catalytically active DNA-PK
holoenzyme which is a major component of the canonical NHEJ machinery during DSB repair. MRN on the other hand initiates HR (see also fig.
2). Once activated, the DNA damage signalling cascade extends through multiple phosphorylation events primarily via the cell-cycle checkpoint
kinases CHK1 and CHK2. Their signals converge on downstream effectors such as the tumour suppressor protein p53 or the CDC25 protein
phosphatase and WEE1 tyrosine kinase. As a result, CDK activity is inhibited, delaying cell cycle progression from G1 to S (the G1/S
checkpoint) or from G2 to M phase (the G2/M checkpoint). The DNA damage response (DDR) thus orchestrates a variety of cellular outcomes:
the transcriptional programme of the damaged cell is altered and the cell cycle is transiently arrested, thereby facilitating repair of the DNA
lesions. In situations where DNA damage is too severe and cannot be repaired, the DDR triggers apoptosis or senescence.
ADP = adenosine diphosphate; ATM = ataxia telangiectasia mutated protein; ATR = ATM- and Rad3-related; ATRIP = ATR-interacting protein;
CDK = cyclin-dependant kinase; DNA = deoxyribonucleic acid; DNA-PK = DNA-dependant protein kinase; DNA-PKcs = DNA-PK catalytic
subunit; FANCM = Fanconi anaemia complementation group M; HR = homologous recombination; ICL = interstrand crosslink; MRN =
MRE11-RAD50-NBS1 complex; NEHJ = nonhomologous end joining; PARP = poly(ADP-ribose) polymerase; RPA = replication protein A
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Figure 2
DNA double-strand break (DSB) repair.
DSBs are predominantly repaired by two distinct pathways: NHEJ or HR. NHEJ operates throughout the cell cycle, but mainly during the G1 and
G2 phases, whereas HR peaks in S phase. Rapid association of the Ku70/80 heterodimer to DSBs promotes NHEJ by recruiting DNA-PKcs.
DNA ends are processed by the nucleolytic activity of Artemis, followed by religation catalysed by a complex of XLF, Ligase IV (Lig4) and
XRCC4. Alternatively, MRN, which is initially recruited to DSBs in competition with Ku70/80, initiates DSB resection together with CtIP thereby
promoting HR. 53BP1 antagonises BRCA1 in DSB resection. Extensive DSB resection by other nucleases and formation of RPA-coated ssDNA
stimulates the activation of ATR. Displacement of RPA by RAD51 is mediated by BRCA2 and PALB2, resulting in the formation of RAD51
nucleoprotein filaments. Subsequent strand invasion into the homologous DNA template and capturing of the second DNA end leads to the
formation of a double Holliday junction, which is processed by resolvases. Finally, the DNA is sealed by ligases to accomplish error-free repair
of the DSB.
53BP = p53 binding protein; ATM = ataxia telangiectasia mutated protein; CtBP = C-terminal binding protein; CtIP = CtBP-interacting protein;
DNA = deoxyribonucleic acid; DNA-PK = DNA-dependant protein kinase; DNA-PKcs = DNA-PK catalytic subunit; HR = homologous
recombination; MRN = MRE11-RAD50-NBS1 complex; NEHJ = nonhomologous end joining; PALB1/2 = partner and localiser of BRCA1/2; RPA
= replication protein A; ssDNA = single-stranded DNA; XLF = XRCC4-like factor; XRCC4 = X-ray repair cross-complementing protein 4
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Figure 3
Synthetic lethality.
Synthetic lethality is defined as a combination of mutations or perturbations in two or more genes that leads to cell death, whereas inactivation
of any one of the genes alone does not. Perturbation of genes can occur through genetic mutation or silencing, depletion by RNAi or inhibition
by SMIs and is depicted by a red cross. If genes that are essential for a certain DNA repair pathway (e.g. gene A) are inactivated in normal cells,
alternative pathways with functional genes (e.g. gene B) are utilised to respond to DNA damage. Conversely, cancer cells mutated or silenced
for a component of a DDR pathway are compromised in their ability to process DSBs. These cells then rely on alternative DNA repair pathways
to repair the breaks. Therefore, inhibition of the alternative pathway will cause cell death due to persisting DSBs. Please refer to main text for
details about the example given for synthetic lethality between BRCA1/2 mutation and PARP inhibition.
ADP = adenosine diphosphate; BER = base excision repair; DDR = DNA damage response; DNA = deoxyribonucleic acid; DSB = double-strand
break; HR = homologous recombination; PARP = poly(ADP-ribose) polymerase; RNA = ribonucleic acid; RNAi = RNA interference; SMI = small
molecule inhibitor
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